Novartis announced today the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN). Dr. Moosmayer will join Novartis on December 1, 2018 and will be based in Basel, Switzerland. He succeeds Shannon Thyme Klinger who was recently appointed Group General Counsel.
Roche’s Alecensa approved in China
Latest NewsRoche AG’s ALK blocker Alecensa (alectinib) has been granted market approval by China National Drug Administration as first line NSCLC monotherapy in patients with ALK-positive non small cell lung cancer (NSCLC)
Pfizer partners with Biontech in US$425m deal
Latest NewsBioNTech AG has partnered with Pfizer to develop a mRNA-based flu vaccine.
New lupus target unraveled
Latest NewsEGFR agonists support the protective effect of Langerhans against UV-induced damage of skin cells, a hallmark of lupus erythematosus and other autoimmune and dermatologic conditions, a team of US and German researchers report.
Zelluna appoints Dr. Namir Hassan
AppointmentsZelluna Immunotherapy, a biotechnology company specializing in T-cell receptor (TCR) immunotherapies, has announced the appointment of Dr. Namir Hassan as chief scientific officer (CSO).
Small molecule restores liver regeneration
Latest NewsA team of Scots, Belgian and Spanish researchers claim they have found a target to prevent failure of liver regeneration following intoxination or acute injury.
Novartis names Klaus Moosmayer as Chief Ethics Risk and Compliance Officer
AppointmentsNovartis announced today the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN). Dr. Moosmayer will join Novartis on December 1, 2018 and will be based in Basel, Switzerland. He succeeds Shannon Thyme Klinger who was recently appointed Group General Counsel.
Orchard Therapeutics raise US-$150m
Latest NewsLondon-headquartered gene therapy Orchard Therapeutics has closed a US-$150m series C financing round to push MAAs and BLAs of three late-stage gene therapies by 2021.
Sphere Fluidics appoints Dr Tris Vaughan
AppointmentsSphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, announced today that Tris Vaughan, PhD FRSB has joined its scientific advisory board (SAB).
Artios Pharma raise €85m in Series B round
Latest NewsLife Sciences Partners and Andera Partners together with Pfizer Ventures and Novartis Venture Fund have put €85m into the cancer drug development company Artios Pharma Ltd.
Researchers remyelinate neurons
Latest NewsGerman neurogenetics at the Max-Planck-Institute for Experimental Medicine have cured the rare incurable hereditary Charcot-Marie-Tooth disease by simply supplementing the food of mice carrying the disease-causing duplication of the PMP22 gene with lecithin. The phospholipid supplementation enabled Schwann cells deficient in lipid synthesis to restore the insulating myelin sheet around peripheral neurons which is needed to speed up neuronal transmission.